Zevtera (ceftobiprole) / Basilea, MedCap AB, Innoviva - LARVOL DELTA

Staphylococcus pettenkoferi: an underrecognized species with clinically relevant antimicrobial resistance. A comprehensive genomic European study. (PubMed, Emerg Microbes Infect) - "Susceptibility rates were below 70% for cefoxitin, erythromycin, and levofloxacin, whereas high susceptibility (>90%) was observed for vancomycin, teicoplanin, dalbavancin, aminoglycosides, oxazolidinones, trimethoprim-sulfamethoxazole, fusidic acid, and tetracycline. Nearly all isolates (92.1%) were fosfomycin-resistant...This study provides a comprehensive genomic and phenotypic assessment of antimicrobial resistance in S. pettenkoferi, revealing widespread multidrug-resistant lineages, including ceftobiprole- and daptomycin-resistant isolates across distinct clades. These findings underscore the need for continued surveillance and improved diagnostics for this increasingly encountered CoNS species."

Journal • Infectious Disease • Inflammation

Individualized Precision Therapy With Ceftobiprole Guided by PK/PD in Geriatric Populations (clinicaltrials.gov) - P=N/A | N=150 | Recruiting | Sponsor: Chinese PLA General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open

Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right‑Sided Infective Endocarditis Using Model-Based Approaches (IDWeek 2026) - No abstract available

Clinical • Infectious Disease

Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections (IDWeek 2026) - No abstract available

Clinical • Infectious Disease

In vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary US Clinical Isolates Collected in 2025 Following FDA Approval (IDWeek 2026) - No abstract available

Preclinical • Infectious Disease

Discovery of novel benzothiophenes targeting penicillin-binding proteins in gram-positive bacteria | Poster Board #1209 (ACS-Fall 2026) - "We previously identified the benzothiophene compound NDM-335 as a potential inhibitor of PBP4 that overcomes PBP4-mediated resistance to ceftobiprole...Binding studies using biochemical and biophysical assays indicate interaction with PBP2 and secondary affinity for PBP4, supporting a mechanism targeting bacterial cell wall biosynthesis. Together, these findings highlight benzothiophene scaffolds as promising platforms for both antibiotic adjuvant development and direct antibacterial discovery, providing a foundation for future optimization against multidrug-resistant gram-positive pathogens."

Gram positive • Infectious Disease

Discovery of putative inhibitors of PBP4 and PBP2a to combat methicillin-resistant Staphylococcus aureus infection | Poster Board #1247 (ACS-Fall 2026) - "Previously identified scaffold NDM-684 lowers the minimum inhibitory concentration (MIC) of both oxacillin and ceftobiprole (BPR) 16-fold at 60 μM and 25 μM, respectively, and was therefore used as a starting point for a structure-activity relationship study. A library of analogs was synthesized and biologically tested for potentiation of oxacillin and BPR against clinically relevant MRSA isolates, and binding of lead compounds to PBPs was also assessed. Further development of analogs based upon this scaffold that reduce oxacillin and/or BPR MICs below their clinical breakpoints are currently ongoing and are expected to enable potent combination therapies against MRSA."

Infectious Disease

Discovery of novel benzothiophenes targeting penicillin-binding proteins in gram-positive bacteria | Poster Board #1749 (ACS-Fall 2026) - "We previously identified the benzothiophene compound NDM-335 as a potential inhibitor of PBP4 that overcomes PBP4-mediated resistance to ceftobiprole...Binding studies using biochemical and biophysical assays indicate interaction with PBP2 and secondary affinity for PBP4, supporting a mechanism targeting bacterial cell wall biosynthesis. Together, these findings highlight benzothiophene scaffolds as promising platforms for both antibiotic adjuvant development and direct antibacterial discovery, providing a foundation for future optimization against multidrug-resistant gram-positive pathogens."

Gram positive • Infectious Disease

Discovery of putative inhibitors of PBP4 and PBP2a to combat methicillin-resistant Staphylococcus aureus infection | Poster Board #1748 (ACS-Fall 2026) - "Previously identified scaffold NDM-684 lowers the minimum inhibitory concentration (MIC) of both oxacillin and ceftobiprole (BPR) 16-fold at 60 μM and 25 μM, respectively, and was therefore used as a starting point for a structure-activity relationship study. A library of analogs was synthesized and biologically tested for potentiation of oxacillin and BPR against clinically relevant MRSA isolates, and binding of lead compounds to PBPs was also assessed. Further development of analogs based upon this scaffold that reduce oxacillin and/or BPR MICs below their clinical breakpoints are currently ongoing and are expected to enable potent combination therapies against MRSA."

Infectious Disease

Fatal Catheter-Related Hematogenous Disseminated MSSA Sepsis in an Immunocompromised Lung Cancer Patient: A Case Report. (PubMed, Infect Drug Resist) - "Although the treatment regimen was ultimately adjusted to cefoxitin combined with clindamycin and the symptoms of the infection were brought under control, the persistence of the previous infection and a secondary Enterococcus faecalis infection, combined with the progression of lung cancer, ultimately led to multiple organ failure, and the patient died on day 28...Early diagnosis using tNGS and targeted antibiotic therapy are critical. Strict catheter care and infection control measures are essential to prevent such life-threatening complications."

Journal • Acute Kidney Injury • Acute Respiratory Distress Syndrome • Infectious Disease • Lung Cancer • Oncology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • Solid Tumor

Pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) considerations of ceftaroline and ceftobiprole for the treatment of Staphylococcus aureus infections: a systematic review. (PubMed, Int J Antimicrob Agents) - "Ceftaroline and ceftobiprole pharmacokinetics are highly variable in hospitalized patients, potentially compromising attainment of stringent pharmacokinetic/pharmacodynamic targets for S. aureus infections. Intensified doses and prolonged infusions may therefore be necessary to ensure adequate drug exposure."

Journal • PK/PD data • Review • Infectious Disease

Ceftaroline and ceftobiprole monotherapy for the treatment of Staphylococcus aureus infections: a systematic review and Bayesian meta-analysis. (PubMed, J Antimicrob Chemother) - "Current evidence does not demonstrate superiority of ceftaroline or ceftobiprole over standard-of-care therapy for clinical cure in non-urinary S. aureus infections. Estimates remain imprecise and are largely driven by registrational trials and subgroup data. These findings support cautious, indication-specific interpretation rather than routine preference of these agents over established therapies."

Clinical • Journal • Monotherapy • Retrospective data • Review • Infectious Disease

β-lactam susceptibility testing of ampicillin-susceptible non-faecalis enterococcal clinical isolates in France. (PubMed, J Antimicrob Chemother) - "Overall, ampicillin may predict amoxicillin categorization for frequent non-faecalis enterococci, and with the exception of meropenem, most β-lactams may still have clinical value against these species. The different species exhibit distinct MIC distribution patterns for the tested β-lactams. Furthermore, substantial discrepancies observed between GD and BMD methods highlight the limited reliability of GD as an alternative to BMD."

Journal

Development of a 3-Amino-1-carboxymethyl-β-lactam-Based Monocyclic Ceftobiprole Analog. (PubMed, Chem Asian J) - "The target structure was synthesized via a modular approach, employing two Wittig reactions as key steps. Biochemical evaluation revealed that the ethyl ester derivative exhibited significant inhibition of S. pneumoniae PBP1b, highlighting this new framework as a valuable starting point for further optimization."

Journal • Infectious Disease • Pneumonia

STUDY ON INVASIVE PNEUMOCOCCAL DISEASE (IPD) AND COMMUNITY ACQUIRED PNEUMONIA (CAP) IN HOSPITALIZED CHILDREN, ARGENTINA AFTER 11 YEARS PNEUMOCOCCAL CONJUGATED VACCINE(PCV13) IN NATIONAL IMMUNIZATION PROGRAM(NIP) (ISPPD 2026) - "All S were 100% susceptible to rifampicin, vancomycin, ceftaroline and ceftobiprole. S coverage by PCV13: 31.1%; estimated coverage by PCV20 60%.Conclusions - Children <1 yr old have the highest rate of incomplete Spn vaccination rate, then, it is needed to improve vaccine coverage in this age group - Serotype 12F and serotype 3 are the most prevalent Spn isolates in our setting - According to Spn serotype distribution in our setting, PCV13 coverage is 31.1% . - According to Spn S detected in IPD and CAP, PCV20 could increase the coverage 28.9% in children in Argentina"

Clinical • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Rapid Quantification of Ceftobiprole in Human Plasma and Cerebrospinal Fluid by LC-MS/MS and Its Application in Patients with Central Nervous System Infections. (PubMed, Molecules) - "The method was successfully applied to samples from three patients, revealing a CSF penetration range of 11.9% to 36.5%. This validated LC-MS/MS method enables simple and rapid quantification of ceftobiprole in plasma and cerebrospinal fluid, filling the gap in data on its CNS penetration and supporting routine drug concentration monitoring in critically ill patients."

Journal • Infectious Disease

Feasibility verification of fingerstick capillary microsampling replacing venipuncture for therapeutic drug monitoring of 12 antibiotics using a rapid LC-MS/MS assay. (PubMed, Talanta) - "A liquid chromatography tandem mass spectrometry method was developed and validated for the simultaneous quantification of vancomycin, linezolid, voriconazole, sulfamethoxazole, trimethoprim, piperacillin, cefoperazone, ceftazidime, ceftobiprole, meropenem, imipenem, and cilastatin in human serum. By directly obtaining serum, this approach fundamentally avoids the hematocrit effect and matrix conversion issues inherent in whole blood microsampling, offering a minimally invasive TDM strategy fully aligned with the gold standard matrix. This strategy is particularly suitable for special populations such as children, the elderly, and critically ill patients."

Journal

In Vitro Antimicrobial Activity of Ceftobiprole and Comparator Agents Against Streptococcus pneumoniae Responsible for Lower Respiratory Tract Infections in the United States (2016-2020), Including Resistant Subsets and Select Serotypes. (PubMed, Antibiotics (Basel)) - "Ceftobiprole retained activity against isolates resistant to macrolides (98.8%), tetracycline (98.2%), oral penicillin (95.4%), against multidrug-resistant isolates (97.0%), and various serotypes (93.8-100%). Ceftriaxone (97.4%) and amoxicillin-clavulanate (95.1%) also showed elevated susceptibilities overall, but inconsistent results and lower than those observed for ceftobiprole were noted against isolates with elevated penicillin MIC or specific serotypes (i.e., 19A). These in vitro results, coupled with documented clinical efficacy, indicate that ceftobiprole is a valuable option to treat CABP caused by S. pneumoniae in the US."

Journal • Preclinical • Cardiovascular • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

UK Antimicrobial Registry: Virtual Registry-an innovative surveillance approach for monitoring the real-world use and effectiveness of newly licensed antimicrobials in Scotland. (PubMed, JAC Antimicrob Resist) - "Adults (≥18 years) prescribed any of 11 RLAs (cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, imipenem/cilastatin/relebactam, eravacycline, ceftaroline, ceftobiprole, dalbavancin, delafloxacin, oritavancin) between June 2019 and June 2023 were included. UKAR:V shows that linked electronic data can support real-world RLA surveillance. With appropriate data linkage, this model offers a scalable, low-burden approach to monitoring utilization/outcomes providing a sustainable foundation for stewardship/policy and assessment of innovative reimbursement models."

Journal • Real-world evidence • Infectious Disease • Pneumonia • Septic Shock

In vitro activity of β-lactams against contemporary Enterococcus faecalis clinical isolates and performances of disc diffusion testing for prediction of β-lactam susceptibility. (PubMed, Eur J Clin Microbiol Infect Dis) - No abstract available

Journal • Preclinical

Pharmacokinetic/Pharmacodynamic Analysis of High-Dose Daptomycin in Combination with Continuous Infusion Ceftobiprole in a Case Series of Documented Staphylococcal Bacteremia or Endocarditis: Is There Any Room for TDM-Guided Dosing Reduction? (PubMed, Antibiotics (Basel)) - "Targeted therapy with daptomycin plus CI ceftobiprole achieved high PK/PD target attainment and favorable clinical outcomes in staphylococcal BSI and IE. TDM and model-informed precision dosing may enable dose optimization and may improve the balance between efficacy and safety. Multicenter studies are warranted."

Journal • PK/PD data • Cardiovascular • Eosinophilia • Infectious Disease

Exploration of a benzothiophene scaffold for use as adjuvants with β-lactam antibiotics against methicillin-resistant Staphylococcus aureus. (PubMed, RSC Med Chem) - "We previously identified benzothiophene NDM-335 as an inhibitor of PBP4 that overcomes PBP4 mediated resistance to ceftobiprole, and have shown that other PBP4 inhibitor scaffolds can be tuned to overcome PBP2a-mediated resistance. Based upon this precedent, we conducted a structure activity relationship (SAR) study on the NDM-335 scaffold to uncover compounds that overcome PBP2a-mediated oxacillin resistance in MRSA, with the lead compound lowering the minimum inhibitory concentration 32-fold at 5 μM. Further development of this new adjuvant lead could potentially deliver a new combination therapy for treating MRSA infections."

Journal • Infectious Disease

Comparison of ceftobiprole 5 μg disk diffusion, MIC test strip, and broth microdilution for susceptibility testing of Staphylococcus aureus clinical isolates. (PubMed, J Clin Microbiol) - "Ceftobiprole offers a β-lactam option for Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA); however, its susceptibility testing remains insufficiently examined across both European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Food and Drug Administration (FDA) interpretive criteria. We systematically compared MIC Test Strip (MTS) and disk diffusion (DD) with broth microdilution (BMD), demonstrating breakpoint-specific performance for methicillin-susceptible Staphylococcus aureus (MSSA) and MRSA and providing practical recommendations that allow laboratories to report accurate results regardless of the guidelines they follow."

Journal • Infectious Disease

Ceftaroline and ceftobiprole efficacy for the treatment of Staphylococcus aureus infections: a systematic review and Bayesian meta-analysis (ESCMID Global 2026) - No abstract available

Retrospective data • Review • Infectious Disease

Sustained susceptibility of blood stream isolates of methicillin-resistant Staphylococcus aureus (MRSA) to ceftobiprole: a five-year review (ESCMID Global 2026) - No abstract available

Review • Infectious Disease